Gandhi, L., Chu, Q.S., Stephenson, J., Johnson, B.E., Govindan, R., Bonomi, P., Eaton, K., Fritsch, H., Munzert, G. and Socinski, M. (2009) An Open Label Phase II Trial of the Plk1 Inhibitor Bi 2536, in Patients with Sensitive Relapse Small Cell Lung Cancer [SCLC]. Journal of Clinical Oncology, 27, 8108.

has been cited by the following article:

• TITLE: Missing the Target?—Targeted Therapy in Small Cell Lung Cancer

  AUTHORS: Karin R. Purshouse

  KEYWORDS: Oncology, Small Cell Lung Cancer, Targeted Therapy, Drug Development

  JOURNAL NAME: Advances in Lung Cancer, Vol.3 No.3, August 22, 2014

  ABSTRACT: Small cell lung cancer [SCLC] is a devastating form of cancer, with most patients harbouring extensive disease at diagnosis and survival of less than 5% at five years. Progress in novel therapies has been limited. This specialist review explores current targeted therapy options and potential areas of development.